{"id":"aprotinin-inhaled","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Airway irritation"}]},"_chembl":{"chemblId":"CHEMBL1201619","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprotinin inhibits kallikrein, plasmin, and other proteases involved in the coagulation cascade and fibrinolysis. When inhaled, it is intended to reduce excessive protease activity in the lungs, potentially decreasing inflammation, bleeding, and tissue damage in respiratory conditions. This mechanism may help preserve lung function and reduce complications in conditions characterized by excessive proteolytic activity.","oneSentence":"Aprotinin is a serine protease inhibitor that blocks multiple coagulation and fibrinolytic enzymes to reduce bleeding and inflammation in the lungs.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:13.259Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis (inhaled formulation in phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07317050","phase":"PHASE3","title":"Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment","status":"NOT_YET_RECRUITING","sponsor":"Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion","startDate":"2026-03-01","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":156},{"nctId":"NCT04527133","phase":"NA","title":"An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19","status":"UNKNOWN","sponsor":"Aviron LLC","startDate":"2020-06-11","conditions":"COVID-19","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aprotinin (inhaled)","genericName":"Aprotinin (inhaled)","companyName":"Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion","companyId":"fundacion-del-hospital-nacional-de-paraplejicos-para-la-investigacion-y-la-integ","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprotinin is a serine protease inhibitor that blocks multiple coagulation and fibrinolytic enzymes to reduce bleeding and inflammation in the lungs. Used for Cystic fibrosis (inhaled formulation in phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}